Study: New Drug Appears To Slow Alzheimer's

An experimental Alzheimer's drug, Lacona Mob, shows promise in slowing cognitive decline but comes with risks such as brain swelling and financial costs. Clinical trials with 1800 patients revealed moderate benefits over a placebo. The drug targets amyloid proteins, offering hope for patients and caregivers. However, further research is needed to explore additional therapies and ensure safety. The FDA is considering fast-track approval, with a decision expected soon.

What is the role of amyloid in Alzheimer's disease as described in the text?

What is the expected timeline for the FDA's decision on the approval of lacona mob?